666 related articles for article (PubMed ID: 29971666)
1. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
Hernandez L; O'Donnell M; Postma M
Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
3. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
5. Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.
Iannazzo S; Iliza AC; Perrault L
Pharmacoeconomics; 2018 Feb; 36(2):189-204. PubMed ID: 29032493
[TBL] [Abstract][Full Text] [Related]
6. Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Allen F; Montgomery S; Maruszczak M; Kusel J; Adlard N
Value Health; 2015 Sep; 18(6):925-38. PubMed ID: 26409621
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
[TBL] [Abstract][Full Text] [Related]
8. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
12. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
13. How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.
Wiyani A; Badgujar L; Khurana V; Adlard N
Neurol Ther; 2021 Dec; 10(2):557-583. PubMed ID: 34279847
[TBL] [Abstract][Full Text] [Related]
14. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
Visintin E; Tinelli M; Kanavos P
Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
16. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Chevalier J; Chamoux C; Hammès F; Chicoye A
PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
[TBL] [Abstract][Full Text] [Related]
20. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
Nuijten M; Mittendorf T
Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
